CoreVision raises ~¥100M seed round for invasive brain-computer interfaces

What's the deal? CoreVision (芯生视界), a Chinese developer of invasive brain-computer interface (BCI) technology, has closed a seed round of nearly ¥100M (roughly $14M). Matrix Partners China led the round, with participation from Yanyuan FundDealroom has a profile for this one. Try Dealroom →, Shuimu Venture CapitalDealroom has a profile for this one. Try Dealroom →, and Xinglian Capital (Z Fund).

Why now? Brain-computer interfaces have surged into the spotlight globally, driven by Neuralink's first human implants and growing clinical evidence that invasive BCIs can restore communication and motor function. China has been ramping up its own neurotechnology ambitions, with government-backed brain science initiatives and increasing venture interest in the sector.

CoreVision's focus on invasive — as opposed to non-invasive — BCI technology puts it at the higher-risk, higher-reward end of the spectrum, where signal quality is far superior but regulatory and surgical hurdles are steeper.

What could go wrong? Invasive BCIs face significant challenges: lengthy regulatory approval timelines, the complexity of implant surgery, and long-term biocompatibility concerns. The technology remains early-stage worldwide, with only a handful of human trials underway. Commercialisation could take years, and the path from lab to clinical use is expensive and uncertain.

The signal: A near-¥100M seed round is a substantial early bet on invasive BCI in China, and the investor mix is telling — Shuimu Venture Capital (linked to the Tsinghua University ecosystem) and Yanyuan Fund (tied to Peking University) point to deep academic roots feeding directly into commercialisation efforts. With CoreVision still at the early stage and Matrix Partners China leading, the round suggests conviction that China's university-to-startup pipeline in neurotechnology is maturing enough to warrant serious venture backing.